Clinical Trial Update: SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for SC-101 in nectin-4 amplified cancers, including triple-negative breast cancer and hormone receptor-positive breast cancer, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• SC-101

Snippet

Sponsor: Tianjin ConjuStar Biologics Co., Ltd. | Conditions: TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING